Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients

doi:10.19803/j.1672-8629.20250700

Abstract

Abstract: Objective To explore such adverse drug reactions (ADRs) as acute pain caused by sacituzumab tirumotecan for injection and to evaluate its clinical manifestations, potential mechanisms, and management strategies. Methods A retrospective analysis was conducted of two cancer patients who developed acute pain following treatment. Data on patients’ demographics, time to ADR onset, pain manifestations, and interventions was collected. Potential mechanisms were analyzed with reference to the literature. Results Both patients developed acute pain within 4 hours of intravenous infusion. Symptoms were gradually resolved after symptomatic treatment and drug discontinuation. Literature suggested that as a TROP-2-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan for injection might caused pain through such mechanisms as inflammatory mediator release or the “bystander effect”. Conclusion Sacituzumab tirumotecan for injection may cause acute pain. Clinicians should be vigilant about this risk, and close monitoring and prompt interventions during treatment are recommended.

Key words: Sacituzumab Tirumotecan for Injection, Antibody-Drug Conjugate, Acute Pain, Cancer, Adverse Drug Reaction

CLC Number:

Gao Chaozheng, Zhao Yifan, Su Li, Li Ping. Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients[J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 934-937.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250700

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I8/934

References

[1] Sichuan Kelun Botai Biopharmaceutical Co., Ltd. Package Insert for Sacituzumab Tirumotecan for Injection[EB/OL]. (2025-10-10) [2025-10-20]. https://www.kelun-biotech.com/upload/2025-10-20/20141759568.
[2] Yin Y, Fan Y, Ouyang Q, et al.Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(6): 1969-1975.
[3] Zhao S, Cheng Y, Wang Q, et al.Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials[J]. Nat Med, 2025, 31(6): 1976-1986.
[4] Fang W, Li X, Wang Q, et al.Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial[J]. BMJ, 2025, 389: e085680.
[5] Ettorre V M, Palmieri L, Santin A D.Clinical pharmacologic considera-tions for antibody-drug conjugate in gynecologic cancers[J]. Expert Rev Clin Pharmacol, 2025, 18(7): 461-469.
[6] Chang H L, Schwettmann B, McArthur H L, et al. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response[J]. J Clin Invest, 2023, 133(18): e172156.
[7] Bignotti E, Ravaggi A, Romani C, et al.Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody[J]. Int J Gynecol Cancer, 2011, 21(9): 1613-1621.
[8] Kobayashi H, Minami Y, Anami Y, et al.Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma[J]. Virchows Arch, 2010, 457(1): 69-76.
[9] Killock D.Sacituzumab tirumotecan improves OS in mTNBC[J]. Nat Rev Clin Oncol, 2025, 22(6): 382.
[10] Yin Q, Wu L, Han L, et al.Immune-related adverse events of immune checkpoint inhibitors: a review[J]. Front Immunol, 2023, 14: 1167975.
[11] Zhao Shidi, Ran Ran, Wang Quanfang, et al.Research progress of antibody-drug conjugate in treatment of breast cancer[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2024, 43(3): 161-170.
[12] Nguyen T D, Bordeau B M, Balthasar J P.Mechanisms of ADC toxicity and strategies to increase ADC tolerability[J]. Cancers (Basel), 2023, 15(3): 713.
[13] Li X, Zhang L, Hu S, et al.Postmarketing safety of sacituzumab govitecan: a pharmacovigilance study based on the FDA adverse event reporting system[J]. Clin Pharmacol Ther, 2024, 115(2): 256-268.
[14] Mahalingaiah P K, Ciurlionis R, Durbin K R, et al.Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates[J]. Pharmacol Ther, 2019, 200: 110-125.
[15] Zhao Shuang, Miao Qiuli, Song Yanqing, et al.Toripalimab-induced hypothyroidism: a case analysis[J]. Chinese Journal of Pharmacovigi-lance(中国药物警戒), 2021, 18(7): 697-699.
[16] Markides D M, Hita A G, Merlin J, et al.Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know[J]. Ann Emerg Med, 2025, 85(3): 214-229.
[17] Krop I E, Kim S B, Martin A G, et al.Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial[J]. Lancet Oncol, 2017, 18(6): 743-754.
[18] Yeh T Y, Luo I W, Hsieh Y L, et al.Peripheral neuropathic pain: from experimental models to potential therapeutic targets in dorsal root ganglion neurons[J]. Cells, 2020, 9(12): 2725.
[19] King G T, Eaton K D, Beagle B R, et al.A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors[J]. Invest New Drugs, 2018, 36(5): 836-847
[20] Bardia A, Mayer I A, Vahdat L T, et al.Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
[21] Modi S, Jacot W, Yamashita T, et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[22] Liu Lianqi, Xiao Dian, Zhong Wu, et al.Related toxicities and research strategies of antibody-drug conjugates[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2024, 21(7): 721-729.
[23] Bechtold-Peters K, Ruggiero A, Vriezen N, et al.CMC regulatory considerations for antibody-drug conjugates[J]. J Pharm Sci, 2023, 112(12): 2965-2980.
[24] Wang Yilu, Zhang Ke, Li Zhengxiang.Signal mining and analysis of adverse events of sacituzumab govitecan[J]. China Pharmacy(中国药房), 2024, 35(20): 2527-2532.